Relapse Rate and Predictive Factors in the Treatment of Hepatitis C in Common Clinical Practice.
Phase of Trial: Phase IV
Latest Information Update: 06 Aug 2012
At a glance
- Drugs Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms RE-CHUT
- Sponsors Merck & Co; Schering-Plough
- 07 Jun 2017 Biomarkers information updated
- 06 Aug 2012 Actual patient number changed from 91 to 97 as reported by ClinicalTrials.gov.
- 06 Aug 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.